Glenmark Pharma, AstraZeneca ink pact for Pulmicort Respules
Bogota: Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that its subsidiary Glenmark Pharmaceuticals Colombia S.A.S. and Astrazeneca Colombia S.A.S. have entered into an exclusive licensing agreement for the commercialization of Astrazeneca's drug Pulmicort Respules.
Under the terms of the agreement, Astrazeneca remains the holder of the registration for Pulmicort Respules and will be responsible for manufacturing and supplying the drug. Glenmark will be responsible for commercialization of Pulmicort Respules in the Colombian market.
Glenmark's current respiratory portfolio in Latin America includes Glemont L (Montelukast + Levocetorizine), Glencet; Levocetirizine, Furomet (Mometasone NS), Complebrez (Formoterol + Budesonide) and Sibet (Salmeterol + Fluticasone).
Glenmark Pharmaceuticals Ltd. (GPL) is a global innovation‐driven pharmaceutical company with presence across Specialty, Generics and OTC business. Globally, Glenmark focuses on the following key therapy areas: respiratory, dermatology and oncology.
The company has been listed on the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the fourth consecutive year in a row, most recently in 2021.
AstraZeneca is a global, science‐led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Read also: Glenmark bags USFDA nod for Metronidazole Vaginal Gel
